FEATURES
Accepted: 2026-01-19
Objective To systematically evaluate the multidimensional impacts of the national centralized volume-based procurement (VBP) policy on the usage of high-value consumables in neurosurgical interventional procedures, cost structure, clinical behavior, and discipline development, providing evidence-based support for subsequent policy iterations. Methods A before-and-after control design was employed, including all cases of neurosurgical interventional procedures using stent grafts at a tertiary hospital from January 1, 2020, to March 31, 2025. The samples were divided into pre-procurement group (1,048 cases) and post-procurement group (942 cases) based on the "Neurointerventional" special VBP, which was implemented on December 15, 2023. Results ①Dose-effect relationship: After centralized procurement, the average number of cases per patient per year increased from 266.70 to 730.20, while the total quantity of single-use materials used decreased by 8 (Z=5.858, P<0.001), indicating a trend of "more cases with less consumption." ②Cost effect: After implementing Value-Based Purchasing (VBP), all types of costs significantly decreased (P<0.0001). The median material costs dropped by 30,860 yuan (Z=13.516, P<0.001), the largest decrease, and the overall median cost decreased by 33,110 yuan (Z=13.117, P<0.001), which was significantly more than other costs like surgery, medication, and testing. This is closely related to the cost of stent materials (Spearman correlation coefficient = 0.703, P<0.001).③Structural effect: The change in the proportion of costs before and after VBP implementation was minimal, only decreasing by 0.46% (Z=4.789, P<0.001), suggesting that "hard costs" are quite rigid. However, costs for medications, testing, diagnosis and treatment, and surgery all decreased, leading to a clear optimization of the cost structure.④Behavioral effect: The average length of hospital stay decreased from 7.69 days to 5.50 days (Z=6.484, P<0.001), suggesting that clinical pathways are being optimized faster.⑤Product substitution: After centralized procurement, the use of drug-coated and cobalt-chromium stents increased by 28.2% (Z=6.287, P<0.001). The use of mirror technology and cobalt-chromium stents increased by 48.3% (Z=10.773, P<0.001), while the use of nickel-titanium and cobalt-chromium stents without surface treatment dropped by 15.8% (Z=3.515, P<0.001) and 67.8% (Z=15.098, P<0.001), respectively. Conclusion The VBP policy promotes efficient use of high-value consumables in neurosurgery, optimization of cost structure, and improvement of clinical efficiency through a volume-for-price and quality assurance mechanism. This offers a Chinese approach to value-based healthcare but still requires attention to rigid cost proportions, new payment models, variations in practitioner behavior, and grassroots-level effects.